HRTX vs. RVNC, MRSN, STOK, GBIO, NGM, VERA, GERN, RCKT, CPRX, and GLPG
Should you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Revance Therapeutics (RVNC), Mersana Therapeutics (MRSN), Stoke Therapeutics (STOK), Generation Bio (GBIO), NGM Biopharmaceuticals (NGM), Vera Therapeutics (VERA), Geron (GERN), Rocket Pharmaceuticals (RCKT), Catalyst Pharmaceuticals (CPRX), and Galapagos (GLPG). These companies are all part of the "medical" sector.
Revance Therapeutics (NASDAQ:RVNC) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability, community ranking and earnings.
Revance Therapeutics currently has a consensus price target of $11.50, suggesting a potential upside of 304.93%. Heron Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 48.65%. Given Heron Therapeutics' higher possible upside, analysts plainly believe Revance Therapeutics is more favorable than Heron Therapeutics.
Revance Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500.
In the previous week, Heron Therapeutics had 7 more articles in the media than Revance Therapeutics. MarketBeat recorded 9 mentions for Heron Therapeutics and 2 mentions for Revance Therapeutics. Heron Therapeutics' average media sentiment score of 0.93 beat Revance Therapeutics' score of 0.79 indicating that Revance Therapeutics is being referred to more favorably in the media.
Heron Therapeutics has a net margin of -61.28% compared to Heron Therapeutics' net margin of -134.10%.
97.7% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by insiders. Comparatively, 6.4% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Heron Therapeutics received 259 more outperform votes than Revance Therapeutics when rated by MarketBeat users. Likewise, 69.01% of users gave Heron Therapeutics an outperform vote while only 63.88% of users gave Revance Therapeutics an outperform vote.
Heron Therapeutics has lower revenue, but higher earnings than Revance Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Heron Therapeutics beats Revance Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Heron Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Heron Therapeutics Competitors List
Related Companies and Tools
